Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Brimonidine on IOP During Dilation
NCT03139708Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brimonidine tartrate + sodium hyaluronate in ocular hypertension (3 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Change in intraocular pressure at 4 hours. Started Sep 2016; status: completed.
02
Drugs
brimonidine tartrate + sodium hyaluronate
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT03139708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139708.